You are here

Sprycel

Bristol-Myers Rises After Drugs Combat Skin, Blood Malignancies

Bloomberg

Mon, 06/7/10 - 09:54 am

Bristol-Myers Squibb

SPRYCEL(R) (dasatinib) Demonstrates Superior Confirmed Complete Cytogenetic Response Rates Compared to Gleevec(R)* in Study of Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

BusinessWire

Sat, 06/5/10 - 12:24 pm

chronic myeloid leukemia

Bristol-Myers cancer drug gets full approval

Yahoo/AP

Tue, 05/26/09 - 09:13 pm

Bristol-Myers Squibb

Pages